INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2021

In mild to moderate Alzheimer's disease, 52 weeks of trans-resveratrol decreased CSF MMP-9 by 46% and reduced brain volume compared to placebo.

Thirty patients with moderate to mild Alzheimer's disease were randomized to receive 500 mg trans-resveratrol orally once daily or placebo for 52 weeks. Trans-resveratrol did not lead to statistically significant changes in blood or CSF Aβ40, whereas placebo participants showed significant decreases in CSF (P = 0.024) and plasma Aβ40 (P = 0.036). Compared with placebo, trans-resveratrol resulted in a significant reduction in brain volume at 52 weeks (P = 0.011) and a 46% decrease in CSF matrix metallopeptidase 9 (P = 0.033).

Study type
Randomized, double-blind, placebo-controlled trial
Who was studied
30 patients with mild to moderate Alzheimer's disease
What was measured
Plasma/CSF Aβ40 and Aβ42, brain MRI volume, and CSF MMP-9 levels

THE PAPER

Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial.

Gu J, Li Z, Chen H, Xu X, Li Y, Gui Y. Neurol Ther, 2021.

PubMed 34402024 ↗DOI 10.1038/s41598-017-00794-5 ↗

Brain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.